Clayton Sleep Insititute Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2007
NCT00665977
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Clayton Sleep Institute

Active Ingredients

Drugs in Phase 4 Trials (1)

sodium oxybate (xyrem) (1 trial)

Drugs in Phase 3 Trials (1)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 4)

Sleep Apnea, Obstructive (Phase 3)

Sleep Apnea Syndromes (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2